Important information for the safe use of Tussionex Pennkinetic Extended-Release Suspension.

Provide Feedback |

Government Resource

Important information for the safe use of Tussionex Pennkinetic Extended-Release Suspension.

August 11, 2010

FDA Consumer Health Information. Silver Spring, MD: US Food and Drug Administration; March 11, 2008.

This announcement alerts parents and health care professionals about the potentially fatal dangers of Tussionex Pennkinetic Extended-Release Suspension, a prescription cough medicine that should not be used in children younger than 6 years.

Free full text

Related information

Related Resources From the Same Author(s)

Five Medication Safety Tips for Older Adults.

February 15, 2024

FDA 101: How to Use the Consumer Complaint System and MedWatch.

April 23, 2012

FDA alerts patients and health care professionals of EpiPen auto-injector errors related to device malfunctions and user administration.

April 8, 2020

Information for healthcare professionals: risk of transmission of blood-borne pathogens from shared use of insulin pens.

March 4, 2015

Using ventilator splitters during the COVID-19 pandemic--letter to health care providers.

February 17, 2021

Safety Problems With Your Child's Medical Device?

July 31, 2013

Making Medical Devices Safer at Home.

January 9, 2013

FDA public health notification: unretrieved device fragments.

March 12, 2019

Medication errors resulting from confusion between risperidone (Risperdal) and ropinirole (Requip).

June 22, 2011

Wear face masks with no metal during MRI exams.

December 16, 2020

Related Resources

FDA advises health care professionals and patients about insulin pen packaging and dispensing.

October 28, 2020

FDA recommends health care professionals discuss naloxone with all patients when prescribing opioid pain relievers or medicines to treat opioid use disorder.

August 5, 2020

FDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individualized tapering.

April 17, 2019

Fentanyl transdermal system (marketed as Duragesic) information.

July 10, 2015

FDA requires label warnings to prohibit sharing of multi-dose diabetes pen devices among patients.

March 11, 2015

Important change to heparin container labels to clearly state the total drug strength.

December 19, 2012

Public Health Notification from FDA: Vail Products Enclosed Bed Systems.

March 28, 2012

Medication errors resulting from confusion between risperidone (Risperdal) and ropinirole (Requip).

June 22, 2011

Promethazine HCl (marketed as Phenergan) Information.

June 23, 2009

Shelhigh, Inc. implantable medical devices.

May 2, 2007

See More About The Topic

Health Care Providers

To sign up for updates or to access your subscriber preferences, please enter your email address below.

5600 Fishers Lane
Rockville, MD 20857
Telephone: (301) 427-1364

Important information for the safe use of Tussionex Pennkinetic Extended-Release Suspension.

Connect With Us

Sign up for Email Updates

Agency for Healthcare Research and Quality

Important information for the safe use of Tussionex Pennkinetic Extended-Release Suspension.

Connect With Us

Sign up for Email Updates

Agency for Healthcare Research and Quality

Submit Your Innovations

Continue as a Guest

Continue Logged In

Submit Your Innovations

Continue as a Guest

Continue logged in

New Users to the PSNet site

Submit Your Training

Continue as a Guest

Continue Logged In

Submit Your Training

Continue as a Guest

Continue Logged In

New Users to the PSNet site

Submit Your Toolkit

Continue as a Guest

Continue Logged In

Submit Your Toolkit

Continue as a Guest

Continue Logged In

New Users to the PSNet site

Submit Your WebM&M Case

Continue as a Guest

Continue Logged In

Submit Your WebM&M Case

Continue as a Guest

Already have a PSNet

Account?

New Users